In SURMOUNT-MAINTAIN, adults who switched to 5 mg of tirzepatide maintained more of their weight loss than those who switched to placebo. After 60 weeks on tirzepatide, 378 adults were randomized three ways for another 52 weeks [2]. Continue at the maximum tolerated dose, drop to 5 mg, or switch to placebo. At week 112, weight sat 21.9% below baseline on the full dose, 16.6% at 5 mg and 9.9% on placebo.
In the trial’s comparison of rescue treatment, 11 of 138 participants (8%) in the maximum-tolerated-dose group received rescue tirzepatide, compared with 35 of 142 (25%) in the 5 mg group and 60 of 90 (67%) in the placebo group[2]. The trial allowed rescue after participants regained at least half the weight they had lost.
The research on weight regain after stopping covers what happened across a broader set of studies. SURMOUNT-MAINTAIN instead measured how a specific dose reduction compared with continuing or stopping tirzepatide.
The reframe
Regain after stopping, the authors suggest, may reflect the re-emergence of biological pressures favoring weight restoration rather than a failure of treatment. [1] That is not a semantic move. If regain is the body resuming a defended position, the question is how much ongoing pressure holds the line. That is a dose question, not a yes-or-no one.
They propose the term adaptive maintenance. It means the minimum intensity that preserves meaningful health benefit, weighed against relapse risk, treatment burden and what the patient wants.
What is established and what is not
Continued obesity medication has the strongest direct evidence for limiting regain[1]. The long-term safety guide covers what multi-year trials reported about adverse events during continued treatment. SURMOUNT-MAINTAIN provides randomized evidence for a particular reduction in tirzepatide dose among adults who reached randomization after the initial treatment period [2].
The narrative perspective also discusses switching to an oral formulation, spacing doses, intermittent rescue therapy and structured lifestyle support [1]. The review of weight regain after stopping treatment summarizes withdrawal trials. The lower-dose tirzepatide trial tested a different approach.
Monitoring during maintenance
The narrative perspective suggests tracking changes in hunger, fullness, weight, waist size and metabolic measures during maintenance [1]. These are proposed warning signs. The authors call for studies to test whether tracking them improves outcomes.
Questions to discuss with your prescriber
Ask what outcomes the prescriber would monitor and when you would review the plan together. The GLP-1 price check can help you compare the costs of plans your prescriber considers appropriate. Ask each provider whether its price changes with the prescribed dose.